trial

The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder

NCTId NCT00044187
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 130
Sponsored by Eli Lilly and Company
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
130
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2001-04
Primary completion
—
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Sibutramine

Sponsors

Eli Lilly and CompanyLead Sponsor

Sites

0 total

Facts & assertions

3 sourced
Enrollment
130
Phase
PHASE4
Status
COMPLETED
relationships
The graph out of here
drug
Sibutramine
drug
lead_sponsor
Eli Lilly and Company
company
indication
Bipolar Disorder
indication
Psychotic Disorders
indication
Psychotic Disorders
indication